SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Sarepta Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMO Products [Member] | $956.87M | $957.58M | $965.57M | $960.36M | $970.60M | $978.16M | $967.17M | $946.99M | $938.41M | $938.57M | $944.52M | $946.63M | 48.5% | -1.4% |
| ELEVIDYS [Member] | $441.99M | $625.71M | $898.73M | $1.17B | $1.22B | $1.06B | $820.79M | $793.44M | $681.56M | $559.84M | $200.36M | $69.11M | 22.4% | -63.8% |
By region
From the segment and revenue-disaggregation notes of Sarepta Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.